Mitchell E. Horwitz
YOU?
Author Swipe
View article: Exploring facilitators and barriers to daily chlorhexidine gluconate bathing in adult patients undergoing hematopoietic stem cell transplantation
Exploring facilitators and barriers to daily chlorhexidine gluconate bathing in adult patients undergoing hematopoietic stem cell transplantation Open
View article: Supplementary Figure S2 from Targeting Hedgehog Signaling with Glasdegib in Patients with Refractory Sclerotic Chronic GVHD: A Report of Two Phase I/II Trials
Supplementary Figure S2 from Targeting Hedgehog Signaling with Glasdegib in Patients with Refractory Sclerotic Chronic GVHD: A Report of Two Phase I/II Trials Open
Phosphoflow analysis of T-cell activation signaling pathways. Flow cytometric measurements of ERK (pT202/204), p38 (pT180/y182), STAT3 (pY705), and STAT5 (pY694) phosphorylation were performed at baseline and after activation with PMA 40 n…
View article: Supplementary Figure S3 from Targeting Hedgehog Signaling with Glasdegib in Patients with Refractory Sclerotic Chronic GVHD: A Report of Two Phase I/II Trials
Supplementary Figure S3 from Targeting Hedgehog Signaling with Glasdegib in Patients with Refractory Sclerotic Chronic GVHD: A Report of Two Phase I/II Trials Open
Fold change from baseline in the absolute count of circulating B cells (C1D1: n=13 responders [R], n=6 non-responders [NR]; C2D1: n=13 R, n=6 NR; C4D1: n=12 R, n=4 NR) (A), naive B cells (C1D1: n=11 R, n=6 NR; C2D1: n=11 R, n=5 NR; C4D1: n…
View article: Supplementary Table S5 from Targeting Hedgehog Signaling with Glasdegib in Patients with Refractory Sclerotic Chronic GVHD: A Report of Two Phase I/II Trials
Supplementary Table S5 from Targeting Hedgehog Signaling with Glasdegib in Patients with Refractory Sclerotic Chronic GVHD: A Report of Two Phase I/II Trials Open
Representativeness of study participants
View article: Supplementary Table S1 from Targeting Hedgehog Signaling with Glasdegib in Patients with Refractory Sclerotic Chronic GVHD: A Report of Two Phase I/II Trials
Supplementary Table S1 from Targeting Hedgehog Signaling with Glasdegib in Patients with Refractory Sclerotic Chronic GVHD: A Report of Two Phase I/II Trials Open
Monoclonal antibodies used in the immunophenotypic analyses
View article: Supplementary Table S4 from Targeting Hedgehog Signaling with Glasdegib in Patients with Refractory Sclerotic Chronic GVHD: A Report of Two Phase I/II Trials
Supplementary Table S4 from Targeting Hedgehog Signaling with Glasdegib in Patients with Refractory Sclerotic Chronic GVHD: A Report of Two Phase I/II Trials Open
Baseline absolute counts and relative distributions of key immune cell subpopulations in patients included in the GETH trial and healthy controls
View article: Supplementary Table S2 from Targeting Hedgehog Signaling with Glasdegib in Patients with Refractory Sclerotic Chronic GVHD: A Report of Two Phase I/II Trials
Supplementary Table S2 from Targeting Hedgehog Signaling with Glasdegib in Patients with Refractory Sclerotic Chronic GVHD: A Report of Two Phase I/II Trials Open
Monoclonal antibodies used in the T-cell co-stimulatory and co-inhibitory molecules expression assays
View article: A retrospective study on beta-blocker use and outcomes in hematopoietic stem cell transplant patients
A retrospective study on beta-blocker use and outcomes in hematopoietic stem cell transplant patients Open
Recent studies have linked beta-blocker (BB) use in critical care settings with improved survival outcomes, potentially due to beta-adrenergic receptor ( β -AR) blockade and associated anti-inflammatory effects. Given the immune system’s r…
View article: 105 | INTERIM RESULTS OF TANDEM CD20‐CD19‐DIRECTED NON‐CRYOPRESERVED CAR‐T CELLS—ZAMTOCABTAGENE AUTOLEUCEL IN RELAPSED/REFRACTORY DIFFUSE LARGE B CELL LYMPHOMA
105 | INTERIM RESULTS OF TANDEM CD20‐CD19‐DIRECTED NON‐CRYOPRESERVED CAR‐T CELLS—ZAMTOCABTAGENE AUTOLEUCEL IN RELAPSED/REFRACTORY DIFFUSE LARGE B CELL LYMPHOMA Open
View article: Outcomes of myeloablative allogeneic hematopoietic cell transplantation with omidubicel vs alternative donor sources
Outcomes of myeloablative allogeneic hematopoietic cell transplantation with omidubicel vs alternative donor sources Open
Omidubicel is a nicotinamide-expanded stem cell product derived from umbilical cord blood (UCB). In a phase 3 randomized trial for high-risk hematologic malignancies, omidubicel had faster neutrophil engraftment and fewer infectious compli…
View article: Long-Term Toxicity after Non-Myeloablative Conditioning Regimens Using Total Body Irradiation
Long-Term Toxicity after Non-Myeloablative Conditioning Regimens Using Total Body Irradiation Open
Recipients of nonmyeloablative conditioning regimens, despite receiving much lower doses of TBI and chemotherapy, are at risk of developing significant, long-term medical conditions comparable with those undergoing myeloablative HSCT.
View article: Long-term survival after unrelated donor marrow transplantation for aplastic anaemia after optimized conditioning regimen: a retrospective multicentre cohort study
Long-term survival after unrelated donor marrow transplantation for aplastic anaemia after optimized conditioning regimen: a retrospective multicentre cohort study Open
US National Institutes of Health.
View article: Impact of Multiple Episodes of Cytomegalovirus Infection on Patient Outcomes in Allogeneic Hematopoietic Stem Cell Transplant Using a Pre-emptive Monitoring Strategy
Impact of Multiple Episodes of Cytomegalovirus Infection on Patient Outcomes in Allogeneic Hematopoietic Stem Cell Transplant Using a Pre-emptive Monitoring Strategy Open
The impact of multiple episodes of clinically significant cytomegalovirus infection (csCMVi) on clinical outcomes during pre-emptive CMV monitoring in allogeneic hematopoietic stem cell transplant recipients (HCT) is not well understood. W…
View article: Gilteritinib as Post-Transplant Maintenance for AML With Internal Tandem Duplication Mutation of <i>FLT3</i>
Gilteritinib as Post-Transplant Maintenance for AML With Internal Tandem Duplication Mutation of <i>FLT3</i> Open
PURPOSE Allogeneic hematopoietic cell transplantation (HCT) improves outcomes for patients with AML harboring an internal tandem duplication mutation of FLT3 ( FLT3-ITD) AML. These patients are routinely treated with a FLT3 inhibitor after…
View article: Bone Marrow Failure due to Aplastic Anemia, Associated With Serous Fat Atrophy, and Treated With Allogeneic, Haploidentical Stem Cell Transplantation: A Case Report
Bone Marrow Failure due to Aplastic Anemia, Associated With Serous Fat Atrophy, and Treated With Allogeneic, Haploidentical Stem Cell Transplantation: A Case Report Open
We describe the case of a 27‐year‐old male, previously healthy though with a social history notable for recreational cocaine use, who developed bone marrow failure due to aplastic anemia (AA) with associated serous fat atrophy (SFA). After…
View article: Financial Toxicity and Quality of Life in Patients Undergoing Stem-Cell Transplant Evaluation: A Single-Center Analysis
Financial Toxicity and Quality of Life in Patients Undergoing Stem-Cell Transplant Evaluation: A Single-Center Analysis Open
PURPOSE We investigated the prevalence of financial toxicity in a population undergoing hematopoietic cell transplantation (HCT) evaluation and measured its impact on post-transplant clinical and health-related quality-of-life outcomes. MA…
View article: Heightened TLR7 signaling primes BCR-activated B cells in chronic graft-versus-host disease for effector functions
Heightened TLR7 signaling primes BCR-activated B cells in chronic graft-versus-host disease for effector functions Open
Chronic graft-versus-host disease (cGVHD) is a debilitating, autoimmune-like syndrome that can occur after allogeneic hematopoietic stem cell transplantation. Constitutively activated B cells contribute to ongoing alloreactivity and autore…
View article: Supplementary Table S4 from Targeting Hedgehog Signaling with Glasdegib in Patients with Refractory Sclerotic Chronic GVHD: A Report of Two Phase I/II Trials
Supplementary Table S4 from Targeting Hedgehog Signaling with Glasdegib in Patients with Refractory Sclerotic Chronic GVHD: A Report of Two Phase I/II Trials Open
Baseline absolute counts and relative distributions of key immune cell subpopulations in patients included in the GETH trial and healthy controls
View article: Supplementary Table S1 from Targeting Hedgehog Signaling with Glasdegib in Patients with Refractory Sclerotic Chronic GVHD: A Report of Two Phase I/II Trials
Supplementary Table S1 from Targeting Hedgehog Signaling with Glasdegib in Patients with Refractory Sclerotic Chronic GVHD: A Report of Two Phase I/II Trials Open
Monoclonal antibodies used in the immunophenotypic analyses
View article: Supplementary Figure S1 from Targeting Hedgehog Signaling with Glasdegib in Patients with Refractory Sclerotic Chronic GVHD: A Report of Two Phase I/II Trials
Supplementary Figure S1 from Targeting Hedgehog Signaling with Glasdegib in Patients with Refractory Sclerotic Chronic GVHD: A Report of Two Phase I/II Trials Open
Expression of T-cell co-stimulatory and co-inhibitory molecules. Expression of CTLA-4, TNFRSF18, PD-1, OX40 and 4-IBB in the CD4+ and CD8+ T-cell compartments was measured by flow cytometry under resting conditions and after 4-hour incubat…
View article: Supplementary Table S5 from Targeting Hedgehog Signaling with Glasdegib in Patients with Refractory Sclerotic Chronic GVHD: A Report of Two Phase I/II Trials
Supplementary Table S5 from Targeting Hedgehog Signaling with Glasdegib in Patients with Refractory Sclerotic Chronic GVHD: A Report of Two Phase I/II Trials Open
Representativeness of study participants
View article: Supplementary Table S1 from Targeting Hedgehog Signaling with Glasdegib in Patients with Refractory Sclerotic Chronic GVHD: A Report of Two Phase I/II Trials
Supplementary Table S1 from Targeting Hedgehog Signaling with Glasdegib in Patients with Refractory Sclerotic Chronic GVHD: A Report of Two Phase I/II Trials Open
Monoclonal antibodies used in the immunophenotypic analyses
View article: Supplementary Table S2 from Targeting Hedgehog Signaling with Glasdegib in Patients with Refractory Sclerotic Chronic GVHD: A Report of Two Phase I/II Trials
Supplementary Table S2 from Targeting Hedgehog Signaling with Glasdegib in Patients with Refractory Sclerotic Chronic GVHD: A Report of Two Phase I/II Trials Open
Monoclonal antibodies used in the T-cell co-stimulatory and co-inhibitory molecules expression assays
View article: Supplementary Figure S1 from Targeting Hedgehog Signaling with Glasdegib in Patients with Refractory Sclerotic Chronic GVHD: A Report of Two Phase I/II Trials
Supplementary Figure S1 from Targeting Hedgehog Signaling with Glasdegib in Patients with Refractory Sclerotic Chronic GVHD: A Report of Two Phase I/II Trials Open
Expression of T-cell co-stimulatory and co-inhibitory molecules. Expression of CTLA-4, TNFRSF18, PD-1, OX40 and 4-IBB in the CD4+ and CD8+ T-cell compartments was measured by flow cytometry under resting conditions and after 4-hour incubat…
View article: Supplementary Figure S2 from Targeting Hedgehog Signaling with Glasdegib in Patients with Refractory Sclerotic Chronic GVHD: A Report of Two Phase I/II Trials
Supplementary Figure S2 from Targeting Hedgehog Signaling with Glasdegib in Patients with Refractory Sclerotic Chronic GVHD: A Report of Two Phase I/II Trials Open
Phosphoflow analysis of T-cell activation signaling pathways. Flow cytometric measurements of ERK (pT202/204), p38 (pT180/y182), STAT3 (pY705), and STAT5 (pY694) phosphorylation were performed at baseline and after activation with PMA 40 n…
View article: Supplementary Table S3 from Targeting Hedgehog Signaling with Glasdegib in Patients with Refractory Sclerotic Chronic GVHD: A Report of Two Phase I/II Trials
Supplementary Table S3 from Targeting Hedgehog Signaling with Glasdegib in Patients with Refractory Sclerotic Chronic GVHD: A Report of Two Phase I/II Trials Open
Monoclonal antibodies used in the phosphoflow analyses of T-cell activation signaling pathways
View article: Supplementary Figure S2 from Targeting Hedgehog Signaling with Glasdegib in Patients with Refractory Sclerotic Chronic GVHD: A Report of Two Phase I/II Trials
Supplementary Figure S2 from Targeting Hedgehog Signaling with Glasdegib in Patients with Refractory Sclerotic Chronic GVHD: A Report of Two Phase I/II Trials Open
Phosphoflow analysis of T-cell activation signaling pathways. Flow cytometric measurements of ERK (pT202/204), p38 (pT180/y182), STAT3 (pY705), and STAT5 (pY694) phosphorylation were performed at baseline and after activation with PMA 40 n…
View article: Supplementary Figure S3 from Targeting Hedgehog Signaling with Glasdegib in Patients with Refractory Sclerotic Chronic GVHD: A Report of Two Phase I/II Trials
Supplementary Figure S3 from Targeting Hedgehog Signaling with Glasdegib in Patients with Refractory Sclerotic Chronic GVHD: A Report of Two Phase I/II Trials Open
Fold change from baseline in the absolute count of circulating B cells (C1D1: n=13 responders [R], n=6 non-responders [NR]; C2D1: n=13 R, n=6 NR; C4D1: n=12 R, n=4 NR) (A), naive B cells (C1D1: n=11 R, n=6 NR; C2D1: n=11 R, n=5 NR; C4D1: n…
View article: Supplementary Table S2 from Targeting Hedgehog Signaling with Glasdegib in Patients with Refractory Sclerotic Chronic GVHD: A Report of Two Phase I/II Trials
Supplementary Table S2 from Targeting Hedgehog Signaling with Glasdegib in Patients with Refractory Sclerotic Chronic GVHD: A Report of Two Phase I/II Trials Open
Monoclonal antibodies used in the T-cell co-stimulatory and co-inhibitory molecules expression assays
View article: Supplementary Table S5 from Targeting Hedgehog Signaling with Glasdegib in Patients with Refractory Sclerotic Chronic GVHD: A Report of Two Phase I/II Trials
Supplementary Table S5 from Targeting Hedgehog Signaling with Glasdegib in Patients with Refractory Sclerotic Chronic GVHD: A Report of Two Phase I/II Trials Open
Representativeness of study participants